author-photo

Murilo Luz

McGill University Health Centre

27

Papers

174

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Clinical-pathological characterization and outcomes of metastatic urothelial cancer in Latin America: Retrospective and translational multicenter database (LACOG 1518).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

2021
Show All
- Source
- Cite
- Save
Citations (1)
Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

2020
Show All
- Source
- Cite
- Save
Citations (1)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (65)